{ "ok": true, "cik": "1674632", "ticker": "BBNX", "name": "Beta Bionics, Inc.", "filings": [ { "form": "8-K", "filed": "2026-09-17", "items": [ "8.01 Other Events", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/1674632/000119312526393322/0001193125-26-393322-index.htm" }, { "form": "8-K", "filed": "2026-09-15", "items": [ "7.01 Regulation FD Disclosure", "8.01 Other Events", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/1674632/000119312526392088/0001193125-26-392088-index.htm" }, { "form": "10-Q", "filed": "2026-07-29", "items": [], "url": "https://www.sec.gov/Archives/edgar/data/1674632/000119312526323777/0001193125-26-323777-index.htm" }, { "form": "8-K", "filed": "2026-07-29", "items": [ "2.02 Results of Operations and Financial Condition", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/1674632/000117184326005010/0001171843-26-005010-index.htm" }, { "form": "8-K", "filed": "2026-05-22", "items": [ "5.07 Submission of Matters to a Vote of Security Holders" ], "url": "https://www.sec.gov/Archives/edgar/data/1674632/000117184326003648/0001171843-26-003648-index.htm" }, { "form": "8-K", "filed": "2026-05-21", "items": [ "7.01 Regulation FD Disclosure", "8.01 Other Events", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/1674632/000117184326003617/0001171843-26-003617-index.htm" } ], "events12m": 10, "sources": { "facts": "https://data.sec.gov/api/xbrl/companyfacts/CIK0001674632.json", "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1674632" }, "license": "Figures as filed with the SEC. Card text CC BY 4.0, POPS4.", "notAdvice": "Reporting, not investment advice. No price targets, no buy or sell views.", "edgar": "🫧 Edgar looked up Beta Bionics, Inc. ($BBNX). Last filing: 8-K (8.01 Other Events), 2026-09-17. 10 event filings (8-K) in the past twelve months.", "auditor": { "changes": [], "nonReliance": [], "restatedSince": null }, "metrics": { "fiscalYearEnd": "2025-12-31", "revenue": 100251000, "revenueGrowth1y": 0.5393864013266998, "revenueGrowthPerYear": 1.8888758530209082, "yearsOfData": 3, "operatingMargin": -0.7150153115679644, "operatingMarginPrior": -0.6948436828204656, "netMargin": -0.7301672801268815, "operatingCashFlow": -50925000, "capitalSpending": 5297000, "freeCashFlow": -56222000, "researchAndDevelopment": 34789000, "researchShareOfRevenue": 0.34701898235429074, "cash": 31576000, "longTermDebt": null, "longTermDebtChange": null, "revenueHistory": [ { "fiscalYearEnd": "2023-12-31", "revenue": 11995000 }, { "fiscalYearEnd": "2024-12-31", "revenue": 65124000 }, { "fiscalYearEnd": "2025-12-31", "revenue": 100251000 } ], "totalEquity": 287610000, "totalAssets": 328743000, "equityRatio": 0.8748779441691534, "returnOnEquity": -0.25451131740899136, "dividendsPaid": null, "payoutRatio": null, "dividendPerShare": null, "dividendYearsRising": null, "dividendCut": null, "priceBased": "Dividend yield, price/earnings and price/book need a share price. The boards carry filings only, so they are not shown.", "range80": { "low": 175089036.47638145, "high": 281412120.23929566, "baseline": 221968859.63030103, "n": 4309, "band": "b01" }, "ifPaceHeld": { "low": 175089036.47638145, "high": 281412120.23929566 } }, "edgarette": "🔖 Exposure: revenue $100.3M (FY2025). Experience: revenue up 53.9% on the year, up 188.9% a year over 2 years; operating margin -71.5%, down from -69.5%. Soundness: equity 87.5% of assets, return on equity -25.5%. Credibility: 3 audited years, moderate weight. Range: 80% of past cases like this landed between $175.1M and $281.4M next year (method v3, set from 4,309 SEC company-years; on a year the method never saw, 83% landed inside). A range, not a forecast. Against peers (60 filers, $50M+ revenue, surgical & medical instruments & apparatus): operating margin -71.5% against a 1.2% median; growth 53.9% against 11.6%.", "peers": { "sic": 3841, "sicDescription": "Surgical & Medical Instruments & Apparatus", "calendarYear": 2025, "minRevenue": 50000000, "depth": 4, "group": "3841", "growth": [ 0.1161, 60 ], "opMargin": [ 0.0124, 60 ], "equityRatio": [ 0.5291, 59 ], "returnOnEquity": [ -0.0233, 55 ], "payoutRatio": [ 0.3812, 8 ] }, "summary": "Beta Bionics (BBNX) grew revenue 53.9% in FY2025 to $100 million, operating margin -71.5% against a 1.2% median for surgical & medical instruments & apparatus, equity 87.5% of assets. Every figure is from the company’s own annual report filed with the SEC.", "chart": "
Beta Bionics, Inc. against its own record and its peers
Operating marginPeer median 1.2%-71.5%Revenue, on the yearPeer median 11.6%53.9%Equity of assetsPeer median 52.9%87.5%Return on equityPeer median -2.3%-25.5%Gold tick: the median of 55–59 peers with $50M+ revenue in surgical & medical instruments & apparatus
", "chartHorizon": null, "backtest": { "tests": 0, "hits": 0, "rate": null, "method": "v3", "note": "hindsight: past years, same calibrated range. The range was calibrated on 2022-2024 SEC data, so years in that window are partly in-sample." }, "registry": { "logged": "2026-09-20T15:20:29.758Z", "hash": "30c4f351ae15f3fc", "status": "open" }, "caution": "Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.", "schema": "pops4.edgarette.card/1", "card": { "summary": "Beta Bionics (BBNX) grew revenue 53.9% in FY2025 to $100 million, operating margin -71.5% against a 1.2% median for surgical & medical instruments & apparatus, equity 87.5% of assets. Every figure is from the company’s own annual report filed with the SEC.", "exposure": { "fiscalYearEnd": "2025-12-31", "revenue": 100251000, "totalDebt": null, "cash": 31576000 }, "experience": { "revenueGrowth1y": 0.5393864013266998, "revenueGrowthPerYear": 1.8888758530209082, "operatingMargin": -0.7150153115679644, "operatingMarginPrior": -0.6948436828204656, "netMargin": -0.7301672801268815, "freeCashFlow": -56222000 }, "soundness": { "equityRatio": 0.8748779441691534, "returnOnEquity": -0.25451131740899136, "payoutRatio": null, "dividendPerShare": null, "dividendYearsRising": null, "dividendCut": null, "note": "Dividend yield, price/earnings and price/book need a share price. The boards carry filings only, so they are not shown." }, "peers": { "sic": 3841, "sicDescription": "Surgical & Medical Instruments & Apparatus", "calendarYear": 2025, "minRevenue": 50000000, "depth": 4, "group": "3841", "growth": [ 0.1161, 60 ], "opMargin": [ 0.0124, 60 ], "equityRatio": [ 0.5291, 59 ], "returnOnEquity": [ -0.0233, 55 ], "payoutRatio": [ 0.3812, 8 ] }, "credibility": { "auditedYears": 3, "weight": "moderate", "standard": "ASOP No. 25", "nonReliance": null, "auditorChange": null }, "range": { "low": 175089036.47638145, "high": 281412120.23929566, "baseline": 221968859.63030103, "coverage": 0.8, "method": "v3", "basis": "next fiscal year revenue: baseline = revenue x (1 + mean of one-year and three-year pace); range = 10th to 90th percentile of how SEC company-years of the same size band actually turned out", "calibratedOn": { "companyYears": 4309, "sizeBand": "b01" }, "kind": "a calibrated range, not a forecast; no view on the share price", "track": { "backtest": { "tests": 0, "hits": 0, "rate": null, "method": "v3", "note": "hindsight: past years, same calibrated range. The range was calibrated on 2022-2024 SEC data, so years in that window are partly in-sample." }, "registry": { "logged": "2026-09-20T15:20:29.758Z", "hash": "30c4f351ae15f3fc", "status": "open" }, "scorecard": "https://www.pops4.com/boards/scorecard" } }, "caution": "Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.", "sources": { "facts": "https://data.sec.gov/api/xbrl/companyfacts/CIK0001674632.json", "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1674632" } }, "definitions": { "operatingMargin": "Operating income divided by revenue.", "netMargin": "Net income divided by revenue.", "freeCashFlow": "Cash from operations minus spending on property and equipment.", "researchShareOfRevenue": "Research and development expense for the year as a share of revenue, both as filed.", "equityRatio": "Shareholders equity as a share of total assets, both as filed. Higher means less of the company is owed to someone else.", "returnOnEquity": "Net income for the year against shareholders equity at year end.", "payoutRatio": "Dividends paid as a share of net income, in the year the cash went out.", "dividendYearsRising": "Consecutive years, counted back from the last on record, in which dividend per share rose. A fall ends the run and is reported as dividendCut.", "revenueGrowthPerYear": "Compound annual growth between the first and latest fiscal years shown.", "credibility": "How much weight a record deserves, in the actuarial sense (ASOP No. 25): more audited years, more weight.", "peers": "Medians of SEC filers with $50M+ revenue in the same industry code (SIC), narrowest group with at least 8 filers, calendar-year figures from SEC XBRL frames.", "backtest": "The same if-the-pace-held arithmetic applied to the company's own past years, scored against what it actually reported next. Hindsight, and labelled so." } }